Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rotavirus vaccine - Bio-Farma/Murdoch-Childrens-Research-Institute

Next Previous
Drug Profile

Rotavirus vaccine - Bio-Farma/Murdoch-Childrens-Research-Institute

Alternative Names: RV3 BB; RV3 BB vaccine - Bio Farma/Murdoch Childrens Research Institute; RV3-BB - Bio-Farma/Murdoch-Childrens-Research-Institute; RV3-BB vaccine

Latest Information Update: 04 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Murdoch Childrens Research Institute
  • Developer Bio Farma Indonesia; Murdoch Childrens Research Institute; PATH
  • Class Attenuated vaccines; Rotavirus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Rotavirus infections

Most Recent Events

  • 30 May 2023 PT Bio Farma completes a phase-III clinical trials in Rotavirus infections (In neonates) in Indonesia (PO) (NCT04185545)
  • 09 Sep 2022 PATH and SK Bioscience completes a phase II trial for Rotavirus infections (In neonates, In infants, Prevention) in South Africa (IM) (NCT04344054)
  • 28 May 2021 No recent reports of development identified for phase-I development in Rotavirus-infections(In adolescents, In children, In infants, In neonates, Prevention, In adults) in Indonesia (PO, Drops)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top